Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-09-28 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SAPHNELO APPROVED IN JAPAN FOR SLE
Foreign Filer Report
2021-09-28 English
Saphnelo approved in Japan for SLE
Regulatory Filings Classification · 100% confidence The document is identified by the RNS Number (1886N) and the date stamp (28 September 2021 07:00 BST), indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content announces a specific corporate event: the approval of the drug Saphnelo in Japan by the Ministry of Health, Labour and Welfare (MHLW). This is a material event disclosure, but it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific shareholder vote result (DVA). Since it is a general regulatory announcement concerning a business development (drug approval) that doesn't fit neatly into the other specific categories (like M&A, Capital Change, or Director Dealing), the most appropriate classification is the general regulatory filing category, RNS.
2021-09-28 English
LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT
Foreign Filer Report
2021-09-24 English
Lynparza PROpel trial meets primary endpoint
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8807M' and is dated '24 September 2021'. It contains a headline about clinical trial results ('Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial') and includes quotes from company executives regarding the positive results. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which is the general category for miscellaneous regulatory filings not covered by more specific SEC forms or reports. Since this is a specific announcement of clinical trial data, it is not a full Earnings Release (ER) or Interim Report (IR), nor is it a presentation (IP) or a management discussion (MDA). It fits best under the general regulatory announcement category, RNS.
2021-09-24 English
BOARD COMMITTEE CHANGE
Foreign Filer Report
2021-09-23 English
NEW SUSTAINABILITY COMMITTEE OF THE BOARD
Foreign Filer Report
2021-09-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.